Fig. 3From: Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trialChanges from test-day baseline in FEV1. Estimated mean (adjusted) changes from test-day baseline in FEV1 at post-dose time-points after 4 weeks using the mixed-effect model repeated measures (MMRM) (day 29; range of difference 50 ml to 115 ml, p <0.006 for all comparisons)Back to article page